Daily Ards Research Analysis
Three ARDS-focused studies stand out today: a multicenter pediatric analysis links underweight status to more conservative PEEP settings and higher mortality; a post hoc Markov-model re-analysis of ACURASYS suggests neuromuscular blockade benefits patients with higher baseline life expectancy; and a scoping review supports the SpO2/FiO2 ratio as a pragmatic surrogate for PaO2/FiO2 across settings.
Summary
Three ARDS-focused studies stand out today: a multicenter pediatric analysis links underweight status to more conservative PEEP settings and higher mortality; a post hoc Markov-model re-analysis of ACURASYS suggests neuromuscular blockade benefits patients with higher baseline life expectancy; and a scoping review supports the SpO2/FiO2 ratio as a pragmatic surrogate for PaO2/FiO2 across settings.
Research Themes
- Precision ventilation and nutrition in pediatric ARDS
- Heterogeneous treatment effects of neuromuscular blockade in ARDS
- Non-invasive oxygenation monitoring using S/F ratio
Selected Articles
1. Nutritional Status and Mechanical Ventilation Practices in Pediatric Acute Respiratory Distress Syndrome: A Secondary Analysis of the 2017-2023 PARDSAsia Study.
In a 21-PICU Asian cohort (n=625) of pediatric ARDS, underweight status (41.8%) was associated with more conservative PEEP prescriptions relative to guideline grid values and higher 60-day mortality (adjusted HR 1.85). Findings highlight the interplay between nutritional status and ventilator management decisions.
Impact: This multicenter analysis links nutrition to both ventilator settings and mortality, identifying a modifiable risk factor and potential practice gap in PEEP titration for underweight children.
Clinical Implications: Consider systematic nutritional assessment and optimization in PARDS and avoid unduly conservative PEEP in underweight children; align PEEP/FiO2 choices with guideline grids while individualizing care.
Key Findings
- Underweight prevalence was 41.8% (261/625) among PARDSAsia patients.
- Underweight patients received PEEP/FiO2 combinations a median of 1.7 cm H2O below recommended grid values (p<0.001).
- Underweight status was associated with higher 60-day mortality (adjusted HR 1.85, 95% CI 1.14–3.01).
- Underweight patients were younger than normal/overweight peers.
Methodological Strengths
- Multicenter dataset across 21 PICUs with standardized BMI z-score definitions
- Cox proportional hazards modeling adjusting for confounders
Limitations
- Non-prespecified secondary analysis with potential residual confounding
- Observational design; PEEP decisions not randomized and may reflect clinician bias
Future Directions: Prospective studies to test nutrition-optimized care bundles and protocolized PEEP titration in underweight PARDS, and to evaluate causal pathways.
OBJECTIVES: In this non-prespecified secondary analysis of the PARDSAsia (NCT04068038) 2017-2023 dataset, we describe baseline nutrition status of children with pediatric acute respiratory distress syndrome (PARDS) and determine its association with positive end expiratory pressure (PEEP) during ventilation and mortality. We hypothesized that abnormal nutritional status was associated with adverse outcomes. DESIGN: The dataset included anthropometric and nutritional data, and body mass index (BMI) z scores were obtained using the World Health Organization standards. Underweight is BMI z score less than -1 and overweight is BMI z score greater than +1. PEEP and F io2 combinations, by the standard grid, in underweight, overweight and normal nutrition groups were compared. Cox proportional hazard regression tested the association between nutrition status and 60-day mortality. SETTING: Twenty-one PICUs across Asia, 2017-2023. PATIENTS: PARDSAsia patients met the 2015 International Guidelines for the Diagnosis and Management of PARDS (PALICC) criteria. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Overall, of 693 PARDSAsia patients, we included 625 cases comprising 261 of 625 (41.8%) underweight, 235 of 625 (37.6%) normal, and 129 of 625 (20.6%) overweight patients. Being underweight compared with normal or overweight status, was associated with younger median (interquartile range) age: respectively, 1.0 (0.3, 3.7) vs. 1.4 (0.5, 4.6) vs. 1.9 (0.7, 8.5) years ( p < 0.001). The prescription of PEEP was more conservative in patients who were underweight compared with patients of normal or overweight nutritional status: PEEP/F io2 combinations were, respectively, -1.7 (-3.3, 0.0) vs. -0.9 (-2.7, 0.0) vs. -0.6 (-1.8, 0.4) cm H 2 O below recommended grid value ( p < 0.001). Underweight nutritional status was associated with greater risk of 60-day mortality (adjusted hazard ratio 1.85 [95% CI, 1.14-3.01]). CONCLUSIONS: Underweight nutritional status was prevalent among children within the PARDSAsia 2017-2023 dataset and was associated with poor clinical outcomes. The prescription of PEEP was more conservative in underweight patients compared with those with normal or overweight status.
2. Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial.
Using daily-state Markov modeling of ACURASYS data, cisatracurium appeared to improve survival primarily in patients under 60 years with non-fatal McCabe scores, with estimated survival rising from 0.63 to 0.93. Benefits were not evident in rapidly or ultimately fatal prognostic groups.
Impact: This re-analysis introduces a mechanistically plausible, trajectory-based approach to detect heterogeneous treatment effects of neuromuscular blockade, supporting precision therapy in ARDS.
Clinical Implications: Short-course cisatracurium may be prioritized for ARDS patients with higher baseline life expectancy (e.g., younger, non-fatal McCabe), while avoiding routine use in those with rapidly fatal prognoses.
Key Findings
- Markov chain modeling of daily states (death, ventilated, weaned alive) up to day 90 captured patient trajectories.
- In patients <60 years with non-fatal McCabe scores (n=130), cisatracurium reduced time ventilated and increased estimated survival from 0.63 (placebo) to 0.93.
- No substantial survival difference with cisatracurium in rapidly or ultimately fatal McCabe groups.
- Absence of vasopressor use was associated with reduced probability of remaining ventilated.
Methodological Strengths
- Advanced Markov state-transition modeling using daily clinical states up to 90 days
- Analysis grounded in data from a randomized, multicenter, double-blind trial
Limitations
- Post hoc subgroup analysis with potential for multiplicity and overfitting
- Relatively small subgroup size; findings require external validation
Future Directions: Prospective validation of trajectory-based selection for neuromuscular blockade, including pre-specified HTE analyses and integration with biomarkers.
PURPOSE: The beneficial effects of systematic cisatracurium administration observed in the ACURASYS randomized, multicenter, double-blinded trial may depend on patient-specific factors. This post hoc analysis aimed to explore whether the impact of cisatracurium on mortality varies with baseline characteristics. METHODS: A Markov chain analysis was conducted using daily clinical states from inclusion to day 90: death (state 0), under mechanical ventilation (state 1), or weaned and alive at day 90 (state 2). Patient trajectories were modeled accordingly. RESULTS: Among the 321 included patients, subgroup analysis following univariate analysis focused on 130 individuals under 60 years with non-fatal McCabe scores. Within this subgroup, cisatracurium administration and absence of vasopressor use significantly reduced the probability of remaining ventilated. Estimated survival increased therefore from 0.63 (placebo group, N = 62) to 0.93 (cisatracurium group, N = 68). In contrast, among patients with a rapidly or ultimately fatal prognosis according to McCabe score, the probability of survival did not differ substantially between the placebo and cisatracurium groups. Among patients with a PaO CONCLUSION: The systematic and short-term administration of cisatracurium in patients with moderate-to-severe ARDS appears to confer greater survival benefit in those with a higher baseline life expectancy. Further validation through retrospective and prospective studies is warranted.
3. Non-invasive SpO2/FiO2 ratio (SFR) as surrogate for PaO2/FiO2 ratio (PFR): A scoping review.
Across 32 studies with 81,637 records, the S/F ratio correlated with the P/F ratio and supported diagnostic and prognostic use in acute hypoxemic respiratory failure and ARDS, including predicting ventilation needs around an S/F threshold of 300 during COVID-19. Findings support broader adoption of non-invasive oxygenation monitoring.
Impact: Synthesizes large-scale evidence that S/F ratio can replace P/F ratio when ABG access is limited, enabling equitable, rapid monitoring in diverse settings.
Clinical Implications: Implement S/F-based thresholds for triage and escalation when ABG is delayed or unavailable; integrate S/F monitoring into ARDS screening and ventilatory management protocols.
Key Findings
- Screened 575 records and included 32 studies encompassing 81,637 patient records.
- S/F ratio demonstrated statistically significant sensitivity and specificity as a surrogate for P/F ratio across adult, pediatric, and neonatal populations.
- In COVID-19 cohorts, an S/F threshold around 300 predicted imminent need for mechanical ventilation.
- Evidence supports S/F ratio for diagnostic and monitoring roles in acute lung injury and ARDS.
Methodological Strengths
- Broad literature search across multiple databases with predefined inclusion criteria
- Synthesis across diverse populations and care settings, enhancing generalizability
Limitations
- Scoping review without formal meta-analysis; heterogeneity in measurement protocols
- Potential bias from variable pulse oximetry accuracy and differing S/F calibration across studies
Future Directions: Prospective validation of S/F-based thresholds for ARDS diagnosis and management, and standardization of oximetry-derived metrics across devices.
Patient oxygenation significantly impacts clinical outcomes, and continuous monitoring is essential, especially in critical care settings where hypoxia is the leading cause of mortality. PFR (PaO2/FiO2 ratio or P/F ratio) is an invasive method for measuring oxygenation requiring arterial blood gas (ABG) sampling, however it carries complications making non-invasive methods more desirable. SFR (SpO2/FiO2 ratio or S/F ratio), a non-invasive tool based on pulse oximetry, provides a cost-effective and rapid way to monitor oxygenation status, especially in settings where advanced methods are unavailable. A total of 575 articles were screened from databases including Web of Science, Scopus, PubMed, and CINAHL, with 32 articles meeting the inclusion criteria for this scoping review wherein SFR was used as a surrogate for PFR and a diagnostic tool for acute lung injury and ARDS. A total of 81,637 patient records were analyzed, including ABG values, pulse oximetry readings, mechanical ventilator settings, and patient diagnoses. The study population included adults, pediatric patients, and neonates admitted to critical care units, with common diagnoses including acute hypoxemic respiratory failure, ARDS, and COVID-19. In the context of COVID-19, SFR was used to predict the need for mechanical ventilation, with a cut-off of 300 indicating a threshold for imminent ventilation requirement. The studies demonstrated statistically significant sensitivity and specificity for SFR, highlighting its utility as a non-invasive tool for assessing oxygenation status. SFR has shown potential as a reliable non-invasive surrogate for determining oxygenation status across all populations.